» Articles » PMID: 35108706

Papillary Craniopharyngioma: A Type of Tumor Primarily Impairing the Hypothalamus - A Comprehensive Anatomo-Clinical Characterization of 350 Well-Described Cases

Overview
Publisher Karger
Specialties Endocrinology
Neurology
Date 2022 Feb 2
PMID 35108706
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Papillary craniopharyngiomas (PCPs) represent a rare histological type of craniopharyngiomas (CPs) usually involving the hypothalamus. This study systematically analyzes the clinical-anatomical correlation between tumor topography and symptoms related to hypothalamic dysfunction in the largest series of PCPs ever gathered.

Methods: From 5,346 CP reports published from 1856 to 2021, we selected 350 well-described cases of the squamous-papillary type. Clinical presentation, tumor topography, severity of hypothalamic adhesion, patient outcome, and tumor recurrence were thoroughly analyzed.

Results: PCPs predominantly occur in adult (96.3%), male (61.7%) patients presenting with headache (63.4%), visual alterations (56.2%), and psychiatric disturbances (50.4%). Most PCPs are solid (50%), round (72%) lesions that occupy the third ventricle (3V, 94.8%) and show low-risk severity adhesions to the hypothalamus (66.8%). Two major topographical categories can be found: strictly 3V (57.5%), growing above an intact 3V floor, and not-strictly or infundibulo-tuberal (32.9%), expanding at the infundibulum and/or tuber cinereum. The hypothalamic syndrome predominated among strictly 3V PCPs (p < 0.001). Psychiatric symptoms (p < 0.001) and high-risk hypothalamic attachments (p = 0.031) related to unfavorable postoperative outcomes among patients treated from 2006 onwards. The not-strictly 3V topography was identified as the major predictor of high-risk hypothalamic attachments (71.2% correctly predicted), which, along with incomplete tumor removal (p = 0.018), underlies the higher tumor recurrence of this topography (p = 0.001).

Conclusions: This systematic review evidences that PCP topography is a major determinant of hypothalamic-related symptoms, type of hypothalamic attachments, and tumor recurrence rate. Accurate preoperative definition of PCP-hypothalamus relationships is essential for the judicious, safe management of these complex lesions.

Citing Articles

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.

Ainiwan Y, Li H, Zheng Y, Wei S, Peng J, Nie J Acta Neuropathol Commun. 2025; 13(1):46.

PMID: 40033395 PMC: 11874662. DOI: 10.1186/s40478-025-01972-7.


Factors influencing fear of disease recurrence in postoperative craniopharyngioma patients.

Zhang L, Zhang Y, Pu J, Li Z Am J Transl Res. 2025; 17(1):188-199.

PMID: 39959246 PMC: 11826155. DOI: 10.62347/UVVD7610.


Development and validation of a radiomics nomogram for preoperative prediction of BRAF mutation status in adult patients with craniopharyngioma.

Qiao N, Li C, Zheng F, Zhang L, Ma G, Jia Y Neurosurg Rev. 2024; 48(1):8.

PMID: 39729136 DOI: 10.1007/s10143-024-03170-w.


Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review.

Hanona P, Ezekwudo D, Anderson J Front Oncol. 2024; 14:1464362.

PMID: 39664200 PMC: 11631891. DOI: 10.3389/fonc.2024.1464362.


Distinction of papillary and adamantinomatous craniopharyngioma: Clinical features, surgical nuances and hypothalamic outcomes.

Yang L, Liu Y, Wang C, Feng Z, Yu L, Pan J Neoplasia. 2024; 57:101060.

PMID: 39357265 PMC: 11474188. DOI: 10.1016/j.neo.2024.101060.